# Envista Holdings Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Envista Holdings Corp). ## Overview Envista Holdings Corp is a U.S.-based dental products company built around more than 30 brands, including Nobel Biocare, Ormco, DEXIS, and Kerr. It sells implants, orthodontics, imaging, restorative, endodontic, rotary, and infection-prevention products used by dental professionals to diagnose, treat, and prevent oral disease. ## Products & services • Dental implant systems and treatment options • Orthodontic solutions, including Spark clear aligners • Digital imaging, software, and visualization systems • Restoratives, endodontics, rotary, and infection prevention • Loupes and other clinical workflow tools - **Specialty Products & Technologies** (64%) — Dental implant solutions and orthodontic products, including clear aligners and related treatment workflows. - **Equipment & Consumables** (36%) — Diagnostic equipment, imaging, software, and consumable dental supplies used in daily practice. - Dental implant systems and related treatment solutions - Orthodontic products, including Spark clear aligners - Digital imaging systems, software, and visualization tools - Restorative, endodontic, rotary, and infection-prevention products - Loupes and other clinical support equipment ## Customers Envista sells primarily to dental specialists and general practitioners, but its customer base also includes dental laboratories, DSOs, hygienists, oral surgeons, educational institutions, governments, and distributors. Demand is driven by clinical need, workflow efficiency, brand trust, and product performance across diagnosis, treatment, and prevention. - **Dental specialists** (primary) — Orthodontists, implantologists, periodontists, and endodontists buy specialty systems and advanced clinical products for complex procedures. - **General dentists** (primary) — General practitioners buy imaging, restorative, endodontic, and consumable products for routine diagnosis and treatment. - **DSOs** (primary) — Dental service organizations buy across multiple categories to standardize products, pricing, and workflows across practices. - **Distributors** (primary) — Third-party distributors, especially Henry Schein, resell Envista products and are important for market access and scale. - **Dental laboratories and institutions** (secondary) — Labs, schools, medical entities, and governments buy specialized equipment and supplies for training, care delivery, and procurement. - Orthodontists, implantologists, periodontists, and endodontists - General dentists and dental hygienists buying daily-use tools - Dental laboratories and oral surgeons needing specialty products - DSOs that standardize purchasing across multiple practices - Third-party distributors such as Henry Schein - Educational, medical, and governmental entities ## Geography Envista serves dental professionals in more than 130 countries, with sales concentrated in North America, Western Europe, and emerging markets. The company’s 2025 revenue mix shows North America as the largest region, while Europe and emerging markets are also meaningful, making foreign exchange, trade policy, and regional demand trends important to results. - **North America** (51.4%) — U.S. and Canada combined; 2025 revenue $1,395.2m of $2,719.5m. - **Western Europe** (22.6%) — 2025 revenue $615.3m of $2,719.5m. - **Other developed markets** (4.5%) — 2025 revenue $122.8m of $2,719.5m. - **Emerging markets** (21.6%) — 2025 revenue $586.2m of $2,719.5m. - Sales span more than 130 countries through direct sales and distributors - North America is the largest region and anchors the commercial network - Western Europe is a major market for implants, imaging, and consumables - Emerging markets are strategically important for growth and penetration - Regional demand and FX swings affect reported sales and margins ## Strategy Envista is focused on portfolio innovation, commercial expansion, and continued investment in its implant and orthodontic platforms, especially Spark clear aligners. Management also emphasizes acquisitions, cost reduction, and manufacturing productivity to fund growth while improving margins. - **Grow Spark clear aligner adoption** (short-term) — Aligners are a key growth engine and benefit from deferred revenue timing and manufacturing scale. - **Invest in portfolio development and product innovation** (medium-term) — New products and technologies support pricing power, customer retention, and category expansion. - **Expand in emerging markets** (medium-term) — These markets offer penetration upside and diversify growth beyond mature regions. - **Use acquisitions to broaden the portfolio** (medium-term) — M&A can add technologies, brands, and geographic reach if integration is successful. - Invest in Spark and other orthodontic technologies to expand adoption - Strengthen implant and digital imaging platforms across global markets - Use cost reduction and productivity to fund growth initiatives - Pursue acquisitions that fit the portfolio or open new categories - Expand commercial reach in emerging markets and DSO channels ## Risks Envista is exposed to cyclical dental demand, distributor concentration, and intense competition across fragmented product categories. It also faces foreign exchange, tariffs, trade policy, geopolitical disruption, and manufacturing concentration risks, while goodwill and intangible assets remain sensitive to impairment if growth or margins weaken. - **Distributor concentration** [high] — Henry Schein represented about 12% of 2025 sales and remains the largest channel partner. - **Demand weakness in key markets** [high] — Dental procedures and equipment purchases can slow when economic conditions soften. - **Trade policy and tariffs** [medium] — Cross-border sourcing and manufacturing make the company sensitive to tariff changes and trade restrictions. - **Foreign exchange volatility** [medium] — A large share of revenue is outside the U.S., so currency moves affect reported sales and margins. - **Goodwill and intangible impairment** [high] — Prior impairment charges show that valuation assumptions can change quickly if performance weakens. - Henry Schein concentration can materially affect sales if purchasing slows - Dental demand can weaken in downturns or in specific regions like China - Tariffs, trade policy, and FX swings can pressure margins and reported sales - Competition from low-cost and specialized rivals can erode pricing - Single-site or limited-site manufacturing creates supply disruption risk - Goodwill and intangibles remain exposed to impairment if performance slips ## Accounting Envista’s reported results are affected by revenue deferral and recognition timing in clear aligner treatment plans, which can shift sales between periods. The company also carries substantial goodwill and intangible assets from acquisitions, so impairment testing and valuation assumptions are important because they can create large non-cash charges. - **Deferred revenue in clear aligner treatment plans** — Can materially affect quarterly growth and comparability - **Goodwill and indefinite-lived intangible impairment** — Can create significant non-cash charges to earnings - **Acquired intangibles amortization** — Affects operating profit and reported margins - **Core sales non-GAAP measure** — Useful for trend analysis but not a GAAP substitute - Clear aligner contracts involve deferred revenue recognition timing - Core sales excludes acquisitions, divestitures, and currency translation - Goodwill and indefinite-lived intangibles require annual impairment tests - Finite-lived intangibles can be written down if cash flows weaken - Acquisition accounting affects amortization and future impairment risk --- *Last updated: 2026-04-28T20:05:13.719402+00:00*